Literature DB >> 21792067

Activation of NK cells by ADCC antibodies and HIV disease progression.

Amy W Chung1, Marjon Navis, Gamze Isitman, Leia Wren, Julie Silvers, Janaki Amin, Stephen J Kent, Ivan Stratov.   

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is of considerable interest as an immune response that may facilitate the control of HIV infection. We studied ADCC responses prospectively in a cohort of 79 HIV-positive subjects followed up for a mean of 2.3 years without antiretroviral therapy. We used a novel assay of the ability of ADCC to activate natural killer (NK) cells, either from the same HIV-positive subject or from a healthy blood donor. We found that ADCC responses to either gp140 Env protein or HIV peptide pools were common in HIV-positive subjects when NK cells from the HIV-positive subject were used but did not correlate with markers of HIV disease progression. In contrast, ADCC responses to whole gp140 Env protein were strongly associated with a slower decline in CD4 T-cell loss when healthy donor NK cells were used as effectors. Our data had implications for induction of the most effective ADCC responses by HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792067      PMCID: PMC3175260          DOI: 10.1097/QAI.0b013e31822c62b9

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

Review 1.  HIV vaccines 1983-2003.

Authors:  Andrew J McMichael; Tomas Hanke
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

2.  Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

Authors:  Chitraporn Karnasuta; Robert M Paris; Josephine H Cox; Sorachai Nitayaphan; Punnee Pitisuttithum; Prasert Thongcharoen; Arthur E Brown; Sanjay Gurunathan; James Tartaglia; William L Heyward; John G McNeil; Deborah L Birx; Mark S de Souza
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

3.  HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.

Authors:  L L Baum; K J Cassutt; K Knigge; R Khattri; J Margolick; C Rinaldo; C A Kleeberger; P Nishanian; D R Henrard; J Phair
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

4.  Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains.

Authors:  K Ljunggren; F Chiodi; G Biberfeld; E Norrby; M Jondal; E M Fenyö
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

5.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

6.  Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.

Authors:  A H Rook; H C Lane; T Folks; S McCoy; H Alter; A S Fauci
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

7.  Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads.

Authors:  Pratip Nag; Jenney Kim; Vytautas Sapiega; Alan L Landay; James W Bremer; Jiri Mestecky; Patricia Reichelderfer; Andrea Kovacs; Jonathan Cohn; Barbara Weiser; Linda L Baum
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

8.  An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Authors:  Guido Ferrari; Justin Pollara; Daniel Kozink; Tiara Harms; Mark Drinker; Stephanie Freel; M Anthony Moody; S Munir Alam; Georgia D Tomaras; Christina Ochsenbauer; John C Kappes; George M Shaw; James A Hoxie; James E Robinson; Barton F Haynes
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

Review 9.  NK cells in HIV infection: paradigm for protection or targets for ambush.

Authors:  Anthony S Fauci; Domenico Mavilio; Shyam Kottilil
Journal:  Nat Rev Immunol       Date:  2005-11       Impact factor: 53.106

10.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.

Authors:  Photini Kiepiela; Kholiswa Ngumbela; Christina Thobakgale; Dhanwanthie Ramduth; Isobella Honeyborne; Eshia Moodley; Shabashini Reddy; Chantal de Pierres; Zenele Mncube; Nompumelelo Mkhwanazi; Karen Bishop; Mary van der Stok; Kriebashnie Nair; Nasreen Khan; Hayley Crawford; Rebecca Payne; Alasdair Leslie; Julia Prado; Andrew Prendergast; John Frater; Noel McCarthy; Christian Brander; Gerald H Learn; David Nickle; Christine Rousseau; Hoosen Coovadia; James I Mullins; David Heckerman; Bruce D Walker; Philip Goulder
Journal:  Nat Med       Date:  2006-12-17       Impact factor: 53.440

View more
  62 in total

1.  Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Authors:  Matthew R Costa; Justin Pollara; Regina Whitney Edwards; Michael S Seaman; Miroslaw K Gorny; David C Montefiori; Hua-Xin Liao; Guido Ferrari; Shan Lu; Shixia Wang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

2.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

3.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 4.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis.

Authors:  Florent Colomb; Leila B Giron; Irena Trbojevic-Akmacic; Gordan Lauc; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

5.  Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes.

Authors:  Vijaya Madhavi; Marjon Navis; Amy W Chung; Gamze Isitman; Leia H Wren; Robert De Rose; Stephen J Kent; Ivan Stratov
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

Review 6.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

7.  Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.

Authors:  Maxime Veillette; Anik Désormeaux; Halima Medjahed; Nour-Elhouda Gharsallah; Mathieu Coutu; Joshua Baalwa; Yongjun Guan; George Lewis; Guido Ferrari; Beatrice H Hahn; Barton F Haynes; James E Robinson; Daniel E Kaufmann; Mattia Bonsignori; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 8.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 9.  HIV antibodies for treatment of HIV infection.

Authors:  David M Margolis; Richard A Koup; Guido Ferrari
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

10.  Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.

Authors:  Wen Shi Lee; Jonathan Richard; Marit Lichtfuss; Amos B Smith; Jongwoo Park; Joel R Courter; Bruno N Melillo; Joseph G Sodroski; Daniel E Kaufmann; Andrés Finzi; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.